logo

For the Inventor, By the Inventor

Stockholm, Sweden

Biovitrum Ab


USPTO Granted Patents = 55



Forward Citations = 505

Loading Chart...
Loading Chart...

108 inventors (with patents filed for the assignee):

goldMedal Gary Johansson (9 out of 14 patents)

silverMedal Patrizia Caldirola (9 out of 11 patents)

bronzeMedal Jerk Vallgårda (9 out of 10 patents)

4.  Björn M Nilsson (8 out of 15 patents)

5.  Jan Tejbrant (8 out of 8 patents)

6.  Marianne Nilsson (8 out of 11 patents)

7.  Ulf J Bremberg (7 out of 14 patents)

8.  Annika Jenmalm Jensen (7 out of 8 patents)

9.  Andrew Mott (7 out of 7 patents)

10.  Guido Kurz (6 out of 7 patents)

11.  Lori Sutin (6 out of 7 patents)

12.  Markus Thor (6 out of 6 patents)

13.  Erik Ringberg (5 out of 17 patents)

14.  Meredith Williams (5 out of 10 patents)

15.  Tjeerd Barf (5 out of 7 patents)


Core Competencies:
11-Beta-Hydroxysteroid Dehydrogenase Inhibitors
Benzofuran Compounds
Aryl Sulfonamide Compounds
Cyclolignans
Pyrimidine Compounds
Amino-Substituted Pyrazinones
Bicyclic Sulfonamide Compounds
Serotonin-Related Diseases
Stable Factor VIII Compositions
Receptor Structures
Animal Models
Pharmaceutical Formulations

55 patents:

1. 8686011 - Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 (2014-04-01),
2. 8541592 - Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (2013-09-24),
3. 7820675 - Benzofuran compounds (2010-10-26),
4. 7718650 - Aryl sulfonamide compounds for treating obesity (2010-05-18),
5. 7709526 - Use of cyclolignans and new cyclolignans (2010-05-04),
6. 7671051 - Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 (2010-03-02),
7. 7666888 - Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 (2010-02-23),
8. 7618961 - Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 (2009-11-17),
9. 7572787 - Substituted naphthalene sulfonamides (2009-08-11),
10. 7566715 - Substituted sulfonamide compounds useful for the prophylaxis and treatment of conditions relating to obesity, type II diabetes and/or disorders of the central nervous system (2009-07-28),
11. 7534794 - Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases (2009-05-19),
12. 7319097 - Compounds (2008-01-15),
13. 7285392 - Methods for identifying active compounds (2007-10-23),
14. 7253196 - Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 (2007-08-07),
15. 7247633 - Pyrimidine compounds and their use (2007-07-24),
Biovitrum AB is a Swedish biopharmaceutical company specializing in the development and commercialization of innovative medicines in the areas of rare diseases, immunology, and inflammation. With a strong focus on research and development, Biovitrum aims to improve the quality of life for patients by addressing unmet medical needs. They collaborate with various stakeholders including academic institutions, healthcare professionals, and patient organizations to bring novel therapies to the market.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

55 Patents

#19 in Stockholm

#122 in Sweden

#12,545 in the World

...
Stockholm, Sweden

Biovitrum Ab

Forward Citations = 505

108 inventors:

goldMedal Gary Johansson (9 out of 14 patents)

silverMedal Patrizia Caldirola (9 out of 11 patents)

bronzeMedal Jerk Vallgårda (9 out of 10 patents)

4.  Björn M Nilsson (8 out of 15 patents)

5.  Jan Tejbrant (8 out of 8 patents)

Please report any incorrect information to support@idiyas.com
Loading…